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Abstract  
Objective 
We describe in detail the burden of infections in adults with diabetes mellitus (DM) within a 
large national population cohort. We also compare infection rates between Type 1 (T1DM) and 
Type 2 (T2DM) patients. 
Research Design and Methods 
A retrospective cohort study compared 102,493 English primary care patients aged 40-89 years 
with a DM diagnosis by 2008 (n=5,863 T1DM, n=96,630 T2DM) to 203,518 age-sex-practice 
matched controls without DM. Infection rates during 2008-15, compiled from primary care and 
linked hospital and mortality records, were compared across 19 individual infection categories. 
These were further summarised as any requiring a prescription, hospitalisation, or as cause of 
death. Poisson regression was used to estimate incidence rate ratios (IRRs) between: (i) people 
with diabetes and controls; (ii) T1DM and T2DM adjusted for age, sex, smoking, BMI and 
deprivation. 
Results 
Compared to controls without diabetes, DM patients had higher rates for all infections, with 
the highest IRRs seen for bone and joint infections, sepsis and cellulitis. IRRs for infection-
related hospitalisations were 3.71 (95%CI 3.27-4.21) for T1DM and 1.88 (95%CI 1.83-1.92) 
for T2DM. A direct comparison of types confirmed higher adjusted risks for T1DM vs. T2DM 
(death from infection IRR = 2.19, 95%CI 1.75-2.74). We estimate 6% of infection-related 
hospitalisations and 12% of infection-related deaths were attributable to DM. 
Conclusions 
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People with diabetes, particularly T1DM, are at increased risk of serious infection representing 
an important population burden. Strategies that reduce the risk of developing severe infections 
and poor treatment outcomes are under-researched and should be explored.  
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Diabetes mellitus (DM) is one of the leading causes of morbidity and mortality across the globe 
and the burden of disease is projected to increase from 415 to 642 million adults between 2015 
and 2040.(1) The association between diabetes (DM) and infection is well known clinically,(2; 
3), and has been linked to a number of causal pathways including impaired immune responses 
within the hyperglycaemic environment(4), as well as potentially other abnormalities 
associated with diabetes such as neuropathy and altered lipid metabolism. It has been described 
in other studies and populations,(5-17) however not all have consistently controlled for 
confounding factors such as smoking, which are more common in people with diabetes and 
associated with infection.(18) Initially, studies mainly considered predominately common 
infections,(6; 8; 12) with few able to include important but rare infections,(7) such as 
endocarditis, or considered the whole range of infection outcomes from health service use,(17) 
to hospitalisation(16) and mortality.(9) Also, few studies have included large numbers of older 
people, for whom infections may be frequent and more serious.(5) Larger recent studies, 
primarily from higher income countries using national datasets have overcome some of these 
limitations,(7-13) but do not always separate Type 1 (T1DM) from Type 2 (T2DM), or only 
consider T2DM.  
In this study, we use a large primary care database in England to comprehensively describe and 
quantify the increased risk of infection in T1DM and T2DM compared to the general 
population, using a wide range of infection categories. A novel feature of our analysis is that 
the study is large enough to identify other characteristics of DM patients that may be associated 
with infection risk such as BMI, smoking, medication use, duration of diabetes, and co-
morbidities or DM complications. We consider the impact of adjustment for common 
confounding factors, and describe how the associations vary by age, sex, region and duration 
of diabetes. Finally, we make a direct comparison of infection risk between T1DM and T2DM 
patients.  
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Research Design and Methods  
Data Source 
The Clinical Practice Research Datalink (CPRD) is a large primary care database representative 
of the population of the United Kingdom (UK).(19) We included 361 general (family) practices 
in England recording data on 1/1/2008, anonymously linked to Hospital Episodes Statistics 
(HES) and Office for National Statistics (ONS) death registration data. In the UK, every 
admission to a National Health Service (NHS) hospital is recorded in HES, and allows for 
identification of primary reason for the admission. Similarly, ONS data allow underlying cause 
of death to be identified. 
 
Study Design 
We carried out a retrospective matched cohort study. Firstly, we identified all patients 
(n=1,488,921) who, as of 1/1/2008, were alive, 40-89 years old, and registered for at least 1 
year with their practice. We then extracted electronic records for all patients (n=104,717) with 
a Read code by 1/1/2008 for DM using nationally agreed-upon codes that practices are 
encouraged to use(20) (Supplemental figure S1). Then from the remaining pool of patients, we 
randomly selected two age-sex-practice matched controls. Matching on practice accounts for 
broad geographical differences and practice-related differences in clinical care and recording 
that may exist. While controls were required to have no DM code by 1/1/2008, they could be 
diagnosed as such after this date. Patients with DM (n=100) not able to be matched to any 
controls were excluded. All patients were followed until the earliest date of: death, de-
registration from practice, practice leaving CPRD or 31/12/2015. 
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Classification of Type 
Whilst DM type is generally recorded via specific Read codes, there are noted concerns around 
misclassification(21). We took a pragmatic approach to resolving this, cross-classifying DM 
Read codes (T1DM, T2DM or non-specific) up to 1/1/2008 with prescribing of anti-DM 
medication in 2007 (insulin, sulphonylureas, biguanides, other antidiabetic) to estimate type at 
baseline. As historical prescribing of anti-DM medication is not reliably available for patients 
with diabetes who were diagnosed many years previously, especially at time of diagnosis, we 
chose not to apply any more detailed prescribing criteria. We excluded patients where there 
was a high potential for misclassification (Supplemental figure S2), although sensitivity 
analyses including them produced similar findings (data not shown). 
For n=6,055 patients with only T1DM codes: only those with insulin prescription(s) in 2007 
were classed as T1DM (n=5,139); we excluded patients with prescriptions for other anti-DM 
medication in 2007 as their type was uncertain (n=759); or if their only insulin was prior to 
2007 (n=93); if they had no insulin in their record ever we assumed the code was wrong and 
classed them as T2DM (n=64). For n=94,450 patients with only T2DM codes: we classified 
them as T2DM (n=93,237) unless they had insulin prescription(s) in 2007 and no other anti-
DM medication previously in their record; in this case they were excluded as their type was 
uncertain (n=1,213). A small group (n=4,112) of patients had both T1DM and T2DM codes 
(or only non-specific codes): if they were prescribed insulin in 2007 with no other anti-DM 
medication in their record they were classed as T1DM (n=724) unless they had codes for 
gestational DM and were thus excluded (n=12); if they were prescribed insulin only prior to 
2007 with no other anti-DM medication they were excluded (n=47); all remaining patients were 
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assumed to be T2DM (n=3,329). Overall this resulted in 5,863 T1DM patients, 96,630 T2DM 
patients and 2,124 excluded patients who could not be clearly classified. 
 
Classification of Infections 
Infections during 2008-15 were classified into 19 different groupings using Read codes for GP 
data and ICD-10 classifications for hospital admissions and cause of death (Supplemental 
Table S1). For each group, any repeated code within 90 days was treated as being the same 
event, with codes >90 days apart assumed to be distinct events. Total number of infection 
events were counted for each patient. Three summary groups were defined: (i) any infection 
with a prescription for antibiotic/antifungal/antiviral drug (BNF 5.1) within 14 days of the 
diagnosis, (ii) any infection event which resulted in a hospital admission, (iii) any infection 
which resulted in death. 
 
Statistical Analyses 
Poisson regression was used to compare rates of infection during follow-up (Stata version 13), 
with an offset accounting for total days registered. When the comparison was between people 
with diabetes and matched controls, Poisson regression conditioned on the matchsets was used, 
which implicitly controls for age, sex and practice. We also explored the impact of further 
adjustment for a range of baseline factors using information recorded up to 2008. These were 
smoking, BMI and deprivation, using the Index of Multiple Deprivation (IMD) a composite 
small-area ecological measure of deprivation based on postcodes.(22) Additionally we adjusted 
for a range of  co-morbidities (chronic kidney disease, heart failure, hypertension, 
hypothyroidism, IHD, peripheral vascular disease, stroke & TIA) and whether they had been 
prescribed a statin or oral steroid in 2007 to see if these could explain differences between 
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people with and without DM.  To look for effect modification, we stratified the model by the 
following variables: gender, age, duration of diabetes and practice region. 
When the comparison was made within those with diabetes, we adjusted directly for age and 
sex, as well as all other confounding factors listed above, and additionally for diabetes 
medication and duration. This was done separately for T1DM and T2DM, and then in a 
combined model with a category for type (dropping diabetes medication from this model). To 
account for clustering by practice, all models used a sandwich estimator to obtain robust 
standard errors. Sensitivity analyses using negative binomial models to correct for 
overdispersion made no material difference (data not shown). 
Finally, the population burden of infection attributable to DM was estimated by calculating 
population attributable risk fractions (PAF).(23) This was done for selected infections for 
T1DM and T2DM separately within 10-year age groups using conditional Poisson regression, 
using the total number of patients registered in the 361 CPRD practices on 1/1/2008 within 
each age-group to calculate the prevalence of DM. An overall PAF for DM was estimated by 
extending the formula, assuming DM type is a polytomous exposure(23).  
 
Results 
The baseline characteristics of patients with and without diabetes are shown in Table 1. T2DM 
patients were on average approximately 11 years older than T1DM (67.6 vs. 56.5 years) and 
more likely to have been diagnosed in the last 5 years (46.6% vs. 8.0%). Mean follow-up time 
for all patients was approximately five-and-a-half years, with 5.0% (n=10,139) of controls 
subsequently receiving a DM Read code during follow-up. 
During follow-up, 56.9% of T2DM patients (n=54,972) had at least one infection accompanied 
by a prescription compared to 46.2% of controls (n=88,568) (Supplemental Table S2). The 
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disparity was broadly similar between T1DM patients (55.0%, n=3,226) and their controls 
(41.3%, n=4,828). For hospitalisations for infection, 15.7% of T2DM patients (n=15,1951) had 
at least one during follow-up compared to 9.8% of controls (n=18,706). Among T1DM, the 
disparity between patients with diabetes (14.6%, n=856) and controls (5.4%, n=630) was 
greater.  
Table 2 summarises infection rates between people with diabetes and controls for T1DM and 
T2DM separately. The resulting IRRs were overall higher for T1DM due to lower rates in their 
(younger) controls, with the largest disparities observed for bone and joint infections (primarily 
osteomyelitis) (IRR=22.34), endocarditis (IRR=6.70) and sepsis (IRR=6.10). For T2DM, the 
largest disparities were seen for bone and joint infections (IRR=4.93), sepsis (IRR=2.25) and 
cellulitis (IRR=2.03). For infections requiring hospitalisation, the IRR was 3.71 (95% CI 3.27-
4.21) for T1DM and 1.88 (95%CI 1.83-1.92) for T2DM. The increased risk of death from 
infection was also markedly higher for T1DM (IRR=7.72, 95% CI 4.47-13.33) than for T2DM 
(IRR=1.92, 95% CI 1.75-2.10). We explored the impact of adjusting for differences in 
smoking, BMI, deprivation and co-morbidity between people with diabetes and controls 
(Supplemental table S3). Generally, associations were attenuated with increasing adjustment, 
but these could not explain the higher overall risk of infection among people with diabetes. For 
example, the adjusted risk of sepsis was still twice as great for people with diabetes than 
without (IRR=2.03, 95% CI 1.86-2.11). Sensitivity analyses excluding controls who developed 
diabetes during the study (Supplemental table S4), did not materially alter our findings. 
The IRRs between those with diabetes and controls for infections requiring hospitalisation were 
stratified by gender, age, duration of diabetes and practice region (Figure 1). Although men 
had higher IRRs for both T1DM (4.07 vs. 3.46) and T2DM (1.96 vs. 1.82), confidence intervals 
overlapped for both types. The increase in relative risk compared to those without diabetes 
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declined with age for both types, but while risk increased with duration of diabetes for T2DM, 
this trend was not seen for T1DM. 
Population attributable risk fractions (PAFs) were estimated for selected infection groups from 
Table 2 (Supplemental table S5). The highest PAFs for DM for individual infections were 
observed for bone and joint infections (22.6%) and sepsis (9.3%). We estimate 6.3% of 
hospitalisations for infections and 12.4% of deaths from infection were attributable to DM.  
Table 3 summarises risk factor IRRs for infection requiring hospitalisation within T1DM and 
T2DM individuals separately. For both types, there were trends of higher risk with increasing 
age, obesity and deprivation. Higher risks among men, and with increasing time since diagnosis 
were only observed for T2DM patients. Insulin prescribing among T2DM patients was a strong 
predictor, and explained much of the trend with duration of diabetes seen in Figure 2. In a 
mutually adjusted model, T2DM patients prescribed a statin in 2007 had lower infection 
hospitalisation rates (IRR=0.83, 95% CI 0.80-0.87), while those prescribed an oral steroid had 
a doubling of a future risk (IRR=1.96, 95% CI 1.85-2.07). 
Finally, we fitted Poisson models only on people with diabetes, with a term for diabetes type 
(Supplemental table S6). After adjusting for age, sex, BMI, smoking and deprivation, the 
increased adjusted risk of any infection plus a prescription was small, but still statistically 
significant, for T1DM (IRR=1.09, 95% CI 1.05-1.13) directly compared to T2DM. However, 
the higher risks of hospitalisation for infection (IRR=1.63, 95% CI 1.50-1.76) and death from 
infection (IRR=2.19, 95% CI 1.75-2.74) were not explained by adjusting for the different 
baseline characteristics between T1DM and T2DM patients.  
 
Discussion 
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In a large English primary care database, we have detailed the increased risk of infection among 
people with diabetes compared to the general population. Organ systems where bacterial 
infections predominate (pneumonia, sepsis, endocarditis, skin, bone and joint infections) as 
well as fungal diseases (mycoses) were associated with substantial increases in magnitude 
among both T1DM and T2DM patients, but risks were consistently higher for T1DM. Among 
people with diabetes, those at highest risk of infection events and poor outcomes 
(hospitalisation) were patients who were older (aged ≥70 years), morbidly obese (BMI >40), 
currently smoking, had a longer duration of DM (T2DM only), had serious co-morbidities and 
were living in more deprived areas. 
 
Strengths and limitations 
The strengths of our analyses are the large size of the dataset including many older patients, 
length of follow-up (up to 7 years), and comprehensiveness of the infections outcomes by 
utilising linkage of data from primary care, hospital episodes and mortality. This large sample 
size has enabled us to consider the importance of several factors rarely considered in previous 
research including key effect modifiers of the possible risk of infectious disease and more 
serious outcomes, including age, socio-economic status, BMI, type and duration of DM, and 
medication use. This level of detail permits a more nuanced assessment of the characteristics 
of patients most at risk of infectious diseases and poor infection outcomes, who may benefit 
from more targeted education and monitoring strategies.  
The large sample size allowed for a detailed and novel investigation of T1DM, overcoming the 
lack of statistical power in other smaller studies. Although some have expressed concerns about 
the quality of DM type coding in UK primary care data,(21) and more complex algorithms to 
classify patients have been proposed,(24) only a small proportion of DM patients by 2008 had 
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solely non-specific codes, or codes for both types of diabetes on their electronic record. While 
we cannot discount some misclassification, we required all patients coded as T1DM to be in 
receipt of insulin without any other anti-DM medication in the year before baseline, creating a 
clearly defined T1DM group, excluding patients otherwise. Any misclassification of true 
T1DM patients being incorrectly coded as T2DM would be a small contribution to the larger 
overall group of T2DM. Regardless of misclassification, we have still produced striking 
findings between those coded as T1DM and T2DM in UK primary care. Our finding that about 
1-in-4 (25.8%) T2DM patients were not in receipt of any recent anti-DM medication in 2007 
is consistent with other recent data.(24) Although our design allowed the population controls 
to receive diabetes diagnoses during follow-up, sensitivity analyses excluding these controls 
did not materially alter our findings. 
Another potential limitation was that our analyses were limited to ages 40+ in 2008, thus 
missing a significant proportion of all T1DM patients.  However, we do not expect that this 
would have impacted on our conclusion that T1DM have greater risk.  Indeed, it seems likely 
that the inclusion of younger adults would, if anything, enlarge differences in risk as baseline 
risks in the younger control populations would be extremely low. 
We did not have comprehensive data on the type of infection or organism identified, as this is 
rarely available in primary care, though risk of bacterial and fungal infections appears to be 
increased most substantially among DM patients. Our results were robust to adjustment for key 
confounding factors, but diagnostic bias could be a possible explanation for some of our 
findings, if there is a greater tendency to diagnose infections, prescribe antibiotics, admit to 
hospital and/or code a death as infection related among patients with DM compared to the 
controls without DM. However, more serious infections diagnosed in hospital would be 
supported by laboratory findings, and the associations with DM tended to be strongest for these 
infections. Most of our covariates are likely to be relatively stable over the period of the study, 
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but medication use may vary, and therefore reported associations based on baseline usage may 
be attenuated.  
 
Comparisons with literature 
Our finding of a 47% higher infection rate (accompanied by an antibiotic/antifungal/antiviral 
prescription) for T2DM relative to the general population compares very closely to a 50% 
higher rate of infection in a recent UK study.(11) Previously in the UK, a study also using 
CPRD data between 1990-2007 showed a 53% higher risk of UTI for T2DM,(12) identical to 
our finding (IRR=1.53). Few population studies have looked in detail at a range of specific 
infections, however a large Canadian study of administrative data found elevated risks for 
people with diabetes in two separate cohorts.(7) For example, their RRs for osteomyelitis 
(RR=4.2-4.4), sepsis (RR=2.5), cellulitis (RR=1.8-1.9) are consistent with our IRRs of 4.9 
(bone and joint infections, where 80% of diagnoses were for osteomyelitis), 2.3 and 2.0 
respectively.  
There have been fewer studies reporting on infection outcomes among people with T1DM. The 
largest study used the Australian diabetes register linked to mortality data between 2000-2010 
to report all-ages SMRs of 4.42 for T1DM and 1.47 for T2DM,(9) which compares with IRRs 
of 7.72 and 1.92 respectively in our study (ages 40 and over only). Similarly, the Australian 
data reported elevated morality from septicaemia and osteomyelitis among T1DM.(9) 
Previously, the Dutch National Survey of General Practice compared infections during 2000-2 
between T1DM and T2DM and a control population,(8) and while both types were associated 
with an increased overall risk, the differences between T1DM and T2DM were not consistent. 
The Dutch finding of a doubling of risk for UTI among T1DM patients (OR=1.96)(8) compares 
closely to IRR=1.81 in our study. 
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The near doubling of risk for hospitalisation for infection for T2DM patients we found, 
compared to patients without diabetes, is consistent with data from the US,(17) Australia(14) 
and Canada.(7) Among T1DM patients we estimated the relative risk to be greater (RR=3.71),   
higher than the RR=2.30 estimated from national data from Finland for hospitalisation for 
bacterial infections.(15) However, a Danish study of pneumonia related hospitalisations during 
1997-2005 also found similar higher risks compared to the general population for T1DM than 
T2DM (RR=4.43 vs. 1.23).(16) This study also reported their risk estimates increased with 
duration of diabetes, (16), a finding we replicated for T2DM. However, there was still an 
elevated risk (58%) among those diagnosed in the last 5 years, compared to people without 
diabetes, which compares closely with a 49% increase in hospital treated infections in a large 
Danish study of incident T2DM.(10) 
We found that T2DM patients on insulin at baseline were at double the risk of hospitalisation 
for infection compared to those patients not using insulin, which may reflect some 
misclassification of T1DM patients as T2DM, but more likely is a marker for severity of 
diabetes. A recent American study found a higher risk of hospitalisation for infection among 
DM patients with insulin therapy, but was unable to distinguish between T1DM and 
T2DM.(25) We observed that T2DM patients on statins at baseline were at lower risk of 
hospitalisation for infection, which builds on recent similar findings from the Netherlands 
which found lower antibiotic prescribing among T2DM patients who initiated statins.(26) We 
did not however replicate this finding among T1DM patients, and this warrants further 
exploration. 
 
Implications 
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In higher income countries, it is often thought that the risk of serious infections among people 
with diabetes is now reduced due to improved control of the disease and antibiotic therapy. 
This may be why current UK guidelines for T2DM do not currently mention infection as a 
possible complication, nor offer any specific guidelines for its management and prevention.(27) 
However, our findings show substantially increased risks of infections requiring antibiotics, 
and poor infection outcomes, particularly increases in incidence of potentially severe infections 
(e.g. endocarditis, sepsis, pneumonia), hospitalisation, and infection related mortality. The 
associations with bone and joint infections were particularly striking. Osteomyelitis is a 
potentially devastating infection in any person, and among people with diabetes is associated 
with increased risk of limb amputation.(28)  
The higher rates of infection we consistently observed among T1DM patients, including a 
doubling of risk for infection related mortality compared with T2DM patients, may represent 
a greater underlying susceptibility. Diabetes seems to have many effects on infection risk,(4) 
which include both an abnormal immune response and possibly increased susceptibility 
resulting from common complications of diabetes such as neuropathy and vascular 
insufficiency. Hyperglycaemic environments have been shown to damage neutrophil 
function(29) and also T lymphocyte responses to infection.(30) Additionally, 
polymorphonuclear neutrophil (PMN) cell performance has been shown to be modified in DM 
patients,(31) and may predispose them to greater infection risk. Better understanding of 
potential mechanisms may increase prospects for host or pathogen directed therapies to reduce 
risk,(32) such as the use of metformin in tuberculosis patients.(33) 
Our study was able to report on the increased risk in hospitalisation among older people with 
diabetes where such risks were 3-4 times higher among those aged 80-89 compared with those 
aged 40-49. A high proportion of infection related hospitalisation among older people was for 
pneumonia (35%). It is unclear at present whether improved DM management or earlier 
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diagnosis of infectious disease might reduce these risks and further studies of the prevention 
and management of infections among patients in primary care are required. Targeted education 
strategies among people with diabetes, and their carers could also be trialled to reduce the risks 
of the most serious infection outcomes. These could potentially be highly effective in reducing 
risk and improving quality of life; of the large RCTs of diabetes management, only one (DCCT) 
reported on a very limited range of infection related outcomes, though this showed both short- 
and long-term reductions in risk of infections in the intervention group.(5)  
Our definition of infectious disease in primary care was highly specific, requiring prescription 
of a relevant antibiotic, antifungal or anti-viral drug, in practice mostly an antibiotic. It seems 
possible that increased prescribing of antibiotics, amongst DM patients could be contributing 
to the development of drug resistance and serious antibiotic associated infections such as 
MRSA and Clostridium difficile, though there is limited direct evidence to assess this.(34) 
Reassuringly, unlike a previous study from Denmark,(10) we did not find evidence of 
differential prescribing of broader spectrum antibiotics among DM patients, where there is 
most concern about the development of resistance (data not shown). However, infections 
requiring a prescription were very common among both T1DM and T2DM patients at over 265 
per 1000 DM patients per year, substantially higher than among age-sex matched controls, 
which may of itself help drive the development of antibiotic resistance. 
The estimated population attributable risk of infection associated with diabetes represents a 
considerable burden. For example, we estimate that 6.4% of all hospitalisations for infections 
in people aged 40-89 years in England during 2008-15 are attributable to diabetes; almost 9% 
among those aged 50-69 (Supplemental table S5). For severe infections, this tends to be even 
higher; almost 13% of infection related deaths could be attributed statistically to DM. With the 
UK population steadily ageing, recent estimates have suggested as much as a trebling of the 
prevalence in T2 diabetes between 1991-2013,(35) there is likely to be a substantial an increase 
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in the burden of DM associated infections.(36) Whilst T1DM is comparatively rare, it is also 
increasing globally(37) and is associated with a particularly high risk of infection.  
 
Conclusions 
This cohort study of over 100,000 people with diabetes and over 200,000 controls provides 
robust evidence that individuals with both T1DM and T2DM are at higher risk of a range of 
common infection including skin infections, bone and joint infection, mycoses, pneumonia, 
and more serious rare infections such as sepsis and endocarditis. They are also nearly twice as 
likely to be hospitalised with infection, and 2 to 8 times more likely to die of infection-related 
death, compared to age-sex and practice matched controls. T1DM patients are at roughly 
double the risk of T2DM patients. These data show that infectious disease among people with 
diabetes represent an important population burden. Future research should explore both 
education and management strategies with both patients and their carers to lessen this, such as 
whether improvements in glycaemic control can reduce the risk of developing severe infections 
and poor treatment outcomes. 
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Table 1: Summary of people with diabetes and matched controls on 1/1/2008 
Baseline characteristic People with 
T2DM (n=96,630) 
T2DM Controls 
(n=191,822) 
People with 
T1DM (n=5,863) 
T1DM Controls 
(n=11.696) 
  n % n % n % n % 
Gender Women 43,230 44.7 86,022 44.8 2,431 41.5 4,856 41.5 
 Men 53,400 55.3 105,800 55.2 3,432 58.5 6,840 58.5 
          
Age 40-49 7,571 7.8 15,140 7.9 2,148 36.6 4,295 36.7 
 50-59 16,696 17.3 33,379 17.4 1,550 26.4 3,100 26.5 
 60-69 26,949 27.9 53,779 28.0 1,119 19.1 2,234 19.1 
 70-79 29,223 30.2 57,994 30.1 735 12.5 1,457 12.5 
 80-89 16,191 16.8 31,730 16.5 311 5.3 610 5.2 
          
Time since  >0 to 5 years 44,989 46.6 n/a _ 466 8.0 n/a _ 
diagnosis >5 to 15 years 41,507 43.0 n/a _ 1,495 25.5 n/a _ 
 >15 years 10,134 10.5 n/a _ 3,902 66.6 n/a _ 
          
Current Insulin 13,967 14.5 n/a _ 5,863 100.0 n/a _ 
DM Drugs* Sulphonylureas 31,846 33.0 n/a _ 0 0.0 n/a _ 
 Biguanides 58,216 60.3 n/a _ 0 0.0 n/a _ 
 Other 6,315 6.5 n/a _ 0 0.0 n/a _ 
 None 24,898 25.8 n/a _ 0 0.0 n/a _ 
          
Other Drugs* Statins 74,735 77.3 48,721 25.4 3,876 66.1 1,607 13.7 
 Oral Steroids 6,205 6.4 10,540 5.5 277 4.7 460 3.9 
          
Deprivation  1 – Least  18,138 18.8 41,926 21.9 1,361 23.2 2,922 25.0 
Quintile† 2 22,071 22.8 46,639 24.3 1,444 24.6 2,969 25.4 
 3 20,025 20.7 39,915 20.8 1,194 20.4 2,417 20.7 
 4 20,860 21.6 37,461 19.5 1,155 19.7 2,061 17.6 
 5 – Most 15,458 16.0 25,735 13.4 706 12.0 1,319 11.3 
 Not assigned 78 0.1 146 0.1 3 0.1 8 0.1 
          
Smoking  Never 35,906 37.2 85,814 44.7 2,516 42.9 5,533 47.3 
Status Ex 47,699 49.4 71,064 37.1 2,184 37.3 3,333 28.5 
 Current 12,984 13.4 30,870 16.1 1,161 19.8 2,511 21.5 
 Unknown 41 0.1 4,074 2.1 0 _ 319 2.7 
          
BMI >10 to 20 1,535 1.6 8,964 4.7 234 4.0 505 4.3 
 >20 to 25 14,564 15.1 59,765 31.2 1,944 33.2 3,638 31.1 
 >25 to 30 34,213 35.4 70,329 36.7 2,318 39.5 3,997 34.2 
 >30 to 40 38,193 39.5 33,811 17.6 1,225 20.9 2,033 17.4 
 >40 7,553 7.8 2,554 1.3 106 1.8 213 1.8 
 Not known 572 0.6 16,399 8.6 36 0.6 1,310 11.2 
          
Chronic  Chronic kidney 19,161 19.8 16,606 8.7 839 14.3 441 3.8 
Disease Heart failure 5,035 5.2 4,222 2.2 161 2.8 98 0.8 
 Hypertension 62,216 64.4 67,156 35.0 2,423 41.3 2,346 20.1 
 Hypothyroidism 8,981 9.3 11,947 6.2 882 15.0 533 4.6 
 IHD 21,336 22.1 22,192 11.6 731 12.5 655 5.6 
 Peripheral vascular 5,665 5.9 4,394 2.3 374 6.4 124 1.1 
 Stroke & TIA 8,457 8.8 9,917 5.2 308 5.3 303 2.6 
 
* - Has prescription for drug class during 2007. † - Index of Multiple Deprivation (see methods) 
Note - Patients can appear in multiple drugs and disease categories, so percentages may sum to >100%
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Table 2: Summary of infection rates during 2008-15 and incidence rate ratios (IRRs) among people with diabetes versus matched controls 
Type of Infection People with T2DM 
(n=96,630) 
T2DM 
Controls 
(n=191,822) 
T2DM vs. Controls People with T1DM 
(n=5,863) 
T1DM 
Controls 
(n=11,696) 
T1DM vs. Controls  
 Events Rate† Rate† IRR* (95%CI) Events Rate† Rate† IRR* (95%CI) 
Bone & Joint Infections 1,071 2.26 0.50 4.93 (4.34-5.61) 182 5.75 0.30 22.34 (12.12-41.20) 
(Acute) Cholecystitis 1,035 2.01 1.35 1.62 (1.48-1.77) 51 1.61 0.85 1.92 (1.22-3.03) 
Endocarditis 100 0.20 0.13 1.84 (1.33-2.53) 8 0.25 0.08 6.70 (1.35-33.39) 
Eye Infection 10,986 21.92 17.42 1.26 (1.22-1.30) 638 20.14 14.58 1.38 (1.22-1.56) 
Gastro-Intestinal 3,930 7.90 4.75 1.70 (1.63-1.78) 242 7.64 3.84 2.04 (1.69-2.46) 
Infective Otitis Externa 7,091 14.18 12.11 1.16 (1.11-1.21) 493 15.56 11.08 1.39 (1.18-1.63) 
Lower Respiratory Tract Infection 50,609 101.11 73.36 1.40 (1.38-1.43) 2,554 80.63 54.91 1.50 (1.39-1.62) 
Meningitis 37 0.07 0.05 1.64 (1.02-2.65) 5 0.16 0.03 6.34 (0.67-59.91) 
Mycoses - Candidiasis 11,025 22.20 10.78 2.11 (2.04-2.19) 721 22.76 10.15 2.39 (2.06-2.77) 
Mycoses - Other Fungal 11,954 23.80 18.99 1.25 (1.22-1.29) 783 24.72 17.87 1.40 (1.25-1.57) 
Pneumonia 7,935 15.97 10.68 1.58 (1.53-1.64) 355 11.21 4.54 2.98 (2.40-3.69) 
Sepsis 2,612 5.29 2.58 2.25 (2.10-2.40) 163 5.15 1.15 6.10 (4.28-8.69) 
(Acute) Sinusitis  6,605 13.21 12.06 1.09 (1.04-1.14) 525 16.57 14.15 1.14 (0.98-1.34) 
Skin - Cellulitis 18,974 38.35 19.75 2.03 (1.97-2.08) 995 31.41 11.76 2.84 (2.48-3.25) 
Skin - Other 24,338 48.95 28.83 1.72 (1.69-1.76) 1,858 58.67 27.81 2.15 (1.98-2.35) 
Surgical Site 2,793 5.64 3.50 1.66 (1.57-1.76) 226 7.13 2.92 2.70 (2.14-3.40) 
TB 123 0.25 0.16 1.64 (1.23-2.20) 9 0.28 0.09 2.63 (0.84-8.24) 
(Other) Upper Respiratory Tract Infection 25,843 51.51 40.56 1.27 (1.24-1.30) 1,686 53.22 41.61 1.29 (1.19-1.39) 
Urinary Tract Infection 28,705 57.50 38.95 1.53 (1.49-1.56) 1,490 47.04 27.25 1.81 (1.63-2.01) 
         
Any plus prescription 132,661 265.62 183.60 1.47 (1.46-1.49) 7,842 247.57 152.09 1.66 (1.59-1.74) 
Any as hospitalisation‡ 19,097 38.72 21.89 1.88 (1.83-1.92) 1,178 37.19 11.67 3.71 (3.27-4.21) 
Death from infection§ 1,470 2.99 1.85 1.92 (1.75-2.10) 80 2.53 0.60 7.72 (4.47-13.33) 
 
* – Incidence rate ratios estimated from Poisson model conditioned on matchsets (age-sex-practice matched), † - Rate per 1,000 per year 
‡ – Leading causes: Pneumonia (35%), LRTI (15%), Cellulitis (12%), Gasto-Intestinal (8%), Sepsis (7%), Surgical Site (6%), UTI (4%), Skin-Other (3%) 
§ – Leading causes: Pneumonia (70%), Sepsis (7%), LRTI (5%), Gasto-Intestinal (5%), Endocarditis (4%), Cellulitis (3%) 
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Table 3: Mutually adjusted IRRs for hospitalisation for infection during 2008-15 among 
individuals with diabetes only 
Baseline characteristic People with T2DM (n=96,630) People with T1DM (n=5,863) 
  IRR* 95%CI IRR† 95%CI IRR* 95%CI IRR† 95%CI 
Gender Women 1  1  1  1  
 Men 1.09 1.05-1.12 1.12 1.08-1.16 0.95 0.81-1.11 1.00 0.85-1.17 
          
Age 40-49 1  1  1  1  
 50-59 0.99 0.90-1.10 1.02 0.92-1.12 1.14 0.90-1.44 1.01 0.80-1.27 
 60-69 1.26 1.14-1.39 1.25 1.13-1.38 1.70 1.38-2.09 1.25 1.00-1.56 
 70-79 1.90 1.73-2.09 1.82 1.65-2.01 2.42 1.93-3.04 1.53 1.18-1.98 
 80-89 3.14 2.84-3.47 2.85 2.57-3.16 4.25 3.37-5.36 2.38 1.79-3.16 
          
Duration of >0 to 5 years 1  1  1  1  
Diabetes >5 to 15 years 1.30 1.25-1.35 1.12 1.08-1.17 0.86 0.64-1.16 0.83 0.61-1.13 
 >15 years 1.75 1.66-1.84 1.24 1.16-1.32 0.87 0.65-1.16 0.85 0.64-1.14 
          
Current  Insulin 2.04 1.95-2.12 1.68 1.60-1.76 n/a  n/a  
DM  Sulphonylureas 1.16 1.12-1.20 1.18 1.14-1.23 n/a  n/a  
Drugs‡ Biguanides 0.97 0.94-1.00 0.94 0.91-0.97 n/a  n/a  
 Other 1.01 0.94-1.08 0.94 0.87-1.01 n/a  n/a  
          
Other Drugs‡ Statins 0.93 0.89-0.97 0.83 0.80-0.87 1.13 0.96-1.33 0.94 0.79-1.12 
 Oral Steroids 2.22 2.10-2.35 1.96 1.85-2.07 3.00 2.38-3.78 2.65 2.08-3.37 
          
Deprivation 1 – Least  1  1  1  1  
Quintile§ 2 1.15 1.08-1.21 1.09 1.03-1.16 1.12 0.90-1.40 1.06 0.86-1.31 
 3 1.23 1.16-1.31 1.14 1.07-1.21 1.18 0.93-1.49 1.05 0.84-1.33 
 4 1.37 1.29-1.45 1.23 1.16-1.31 1.64 1.32-2.05 1.46 1.18-1.81 
 5 – Most 1.64 1.54-1.74 1.40 1.31-1.49 1.68 1.32-2.12 1.39 1.08-1.78 
          
Smoking  Never 1  1  1  1  
Status Ex 1.27 1.22-1.32 1.17 1.12-1.21 1.13 0.95-1.36 1.00 0.84-1.19 
 Current 1.69 1.60-1.79 1.58 1.49-1.67 1.49 1.24-1.79 1.42 1.18-1.70 
          
BMI >10 to 20 1.34 1.18-1.53 1.27 1.12-1.45 1.47 1.07-2.01 1.43 1.04-1.97 
 >20 to 25 1  1  1  1  
 >25 to 30 0.93 0.88-0.97 0.93 0.89-0.98 0.96 0.81-1.14 0.95 0.80-1.12 
 >30 to 40 1.18 1.12-1.24 1.13 1.07-1.19 1.16 0.95-1.42 0.99 0.80-1.21 
 >40 2.09 1.94-2.26 1.86 1.73-2.01 1.91 1.18-3.08 1.32 0.83-2.09 
          
Chronic  Chronic kidney  1.49 1.43-1.56 1.26 1.21-1.31 2.35 1.96-2.82 1.94 1.63-2.32 
Disease Heart failure 2.18 2.07-2.30 1.56 1.47-1.64 2.46 1.81-3.35 1.52 1.08-2.16 
 Hypertension 1.00 0.96-1.04 0.96 0.92-0.99 1.43 1.20-1.70 1.27 1.07-1.51 
 Hypothyroidism 1.14 1.08-1.21 1.03 0.97-1.09 0.97 0.80-1.19 0.93 0.77-1.13 
 IHD 1.40 1.35-1.45 1.15 1.11-1.20 1.90 1.59-2.28 1.48 1.23-1.78 
 Peripheral vascular  1.74 1.64-1.84 1.30 1.23-1.38 1.95 1.58-2.40 1.31 1.05-1.62 
 Stroke & TIA 1.56 1.49-1.64 1.39 1.32-1.45 1.84 1.43-2.36 1.49 1.14-1.95 
 
* – Incidence rate ratios estimated from Poisson model conditioned on matchsets (age-sex-practice matched), 
† – Additionally adjusted for all other factors listed in table, ‡ - Has prescription for drug class during 2007. § - 
Index of Multiple Deprivation (see methods). 
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Figure: Incidence rate ratios (IRRs) for hospitalisation for infection during 2008-15 between 
people with diabetes and matched controls stratified by sex, age, duration of diabetes and 
practice region. IRRs are derived from Poisson models conditioned on matchsets (age-sex-
practice matched), which were fitted separately within each subgroup, for T1DM vs. controls 
and T2DM vs. controls individually. 
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Supplemental Figure S1: Overall Study Design  
 
1 – Matched controls were required to have no Diabetic Read codes in their record as of 1/1/2008, but were allowed to become diabetic during follow-up 
  
361 English GP practices 
2008 2015 
104,717 patients 
aged 40-89 on  
QOF diabetes 
register as of 
1/1/2008 and 
registered for at 
least 1 year 
N=96,630 people with T2DM  
N=191,822 age-sex-practice 
matched controls1 
Infection rates 2008-15 compared 
between T2DM & controls (Tables 1-2, 
Figure 2) 
Excluded DM cases with: no 
clear type classification 
(n=2,124), no matched 
control (n=100) 
N=5,863 people with T1DM 
N=11,696 age-sex-practice 
matched controls1 
Infection rates 2008-15 compared 
between T1DM & controls 
(Tables 1-2, Figure 2) 
Infection rates 2008-15 compared 
within (Table 3) and between (Table 4) 
T2DM & T1DM only 
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Supplemental Figure S2: Derivation of Type 1 and Type 2 Diabetes 
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All others 
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ADM ever 
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DM ever 
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All others  
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ADM = Anti-diabetic medicine 
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ADM ever 
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Insulin  
+ ADM in 
2007 
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Any Insulin 
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+ no other 
ADM ever 
+ gestational 
DM ever 
Exclude 
N=12 
Total T1DM patients 
N=5,863 Total T2DM patients 
N=96,630 
What combination of DM OQF Read codes does the 
patient have by January 1st 2008? 
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Supplemental Table S1: ICD-10 and Read codes for Infections 
 ICD-10 Read Codes 
Bone & Joint Infections M00, M86.0-M86.2 N010*, N30..-N303z, N308*, N309*, N30y.-N30zz 
(Acute) Cholecystitis K80, K80.4, K81.0, K81.9 J640*, J643*, J650*, J651z, J666. 
Endocarditis I01.1, I33, I33.0, I33.9, I38, I39, I39.8 A3642, A7422, A932*, A98y3, AB2y0, AB414, G011., G14z., G51*, G54z., G54z3, G54z4, G54zz, Gyu5E 
Eye Infection H10, H10.0, H10.2, H10.3, H10.5, H16*, H44.0,  F400*, F4A*, F4C0.-F4C05, F4C0z, F4C2*, F4C33, F4D1.-F4D13, F4D1z, F4D4., F4D5. 
Gastro-Intestinal A00-A02.0, A02.2-A09.9 A00..-A020., A022*, A02y.-A0z.., A3Ay2 
Infective Otitis Externa H60, H60.0-H60.4, H60.8-H60.9 F501*, FyuN0, FyuN1, FyuN3-FyuN7 
LRTI J20-J22 H06*, H07* 
Meningitis G00-G03.0., G03.8, G03.9 A360., A365., A366., A42*, A4z0., A4z1., A530., A54x1, A553., A721., AB2y2, AB32., Ayu8C, Ayu8D, F00*, F01*, 
F02.., F020., F02z., Fyu00, Fyu01, Fyu03, Fyu04 
Mycoses - Candidiasis B37* AB2-AB2y., AB2y1-AB2z. 
Mycoses - Other Fungal B35-B36.9,B38-B49 AB…-AB1z, AB3..-ABz.. 
Pneumonia A48.1, J12-J18 A3A4., H20..-H2C.., Hyu08-Hyu0H 
Sepsis A02.1, A20.7, A22.7, A26.7, A32.7, A40-A41.9, 
A48.3, O85 
A021., A023., A202., A270100, A271100, A2706, A362., A38*, A396., A3Ay100, A3C*, A545., A98yz12, 
Ayu3E00- Ayu3H00, Ayu3J00, H5y0100, K190600, L090y00, L090z00, L40..11, L293*, L403*, SP25400 
(Acute) Sinusitis  J01* H01* 
Skin - Cellulitis H60.1, K12.2, L03*, N73.0-N73.2 F4D0.11, F4D14, H1y51, H1y71, J083.- J083z00, J0851, J54..11, J540.11, K2723, K2843, K403., K403100, K403z, 
K404., K4040, K405., K4051, K405z, M02..- M0200, M020z-M0210, M021z00, M02z.00, M03..00, M03..13, 
M030*, M031.00, M032-M034000, M034013- M03y000, M03z.00, M03z000, M03zz00, M08.., M080.00, 
M080.13- M086., M088.- M08y.  
Skin - Other A46, A49.0, J34.0, L00-L02.9, L04-L05.9, L08.1-
L08.9, L30.3, L66.3, L66.4, L73.9, N73, N73.8-
N73.9 
A35.., A3B1*, J54..00, J54..12, J540., K403000, K403111, K4041-K404z, K4050, M0...- M01z0, M0201-M0205, 
M0211-M0213, M021z11, M02z.11-M02z.14, M03..11, M03..12, M031.11, M034011, M034012, M03y011, 
M03z100, M03zz11, M04..- M061.00, M062.- M07..00, M072.- M07y100, M07yz- M07z.13, M07z0- M07z2, 
M080.11, M080.12, M087., M09*, M0y*, M0z*, M244.00, M2440- M244111, M2443- M244z 
Surgical Site T79.3, T80.2, T81.4, T82.6, T82,7, T83.5, T83.6, 
T84.5-T84.7, T85.7, T87.4, T88.0 
SP056, SP06.00, SP06.12- SP06A11, SP077, SP078, SP132, SP162, SP25.- SP253, SP255- SP25z, SP33* 
TB A15-A19.9 A1*, Ayu1.00, Ayu10, Ayu11, Ayu13- Ayu16, Ayu18, Ayu19, N304*, N305*, N306* 
(Other) URTI A37-A38, H65.0-H65.1, H66*, J02-J06.9, J36 A33*, A34*, F510.00- F5103, F5200-F520z, F526.-F528., F52z.11, H02*, H03*, H04*, H05*, H15.., Hyu01- 
Hyu03 
UTI N10-N12, N13.6, N15.1, N15.9, N30* K103.12, K104.-K106., K10y.-K10z., K15*, K190*, Kyu10, Kyu1E 
 
* - indicates a wild-card, so include all codes in hierarchy  
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Supplemental Table S2: Summary of infection events per patient during follow up (2008-15) 
Number of 
Infections 
People with T2DM 
(n=96,630) 
T2DM Controls 
(n=191,822) 
People with T1DM 
(n=5,863) 
T1DM Controls 
(n=11,696) 
 n % n % n % n % 
         
Any plus 
prescription 
        
0 41,658 43.1% 103,254 53.8% 2,637 45.0% 6,868 58.7% 
1 22,992 23.8% 42,959 22.4% 1,395 23.8% 2,484 21.2% 
2 12,806 13.3% 20,738 10.8% 745 12.7% 1,083 9.3% 
3 7,482 7.7% 10,702 5.6% 404 6.9% 580 5.0% 
4 4,370 4.5% 5,829 3.0% 273 4.7% 304 2.6% 
5 2,772 2.9% 3,445 1.8% 165 2.8% 142 1.2% 
6+ 4,550 4.7% 4,895 2.6% 244 4.2% 235 2.0% 
         
Any as 
hospitalisation 
        
0 81,435 84.3% 173,116 90.3% 5,007 85.4% 11,066 94.6% 
1 11,865 12.3% 15,522 8.1% 641 10.9% 524 4.5% 
2+ 3,330 3.5% 3,184 1.7% 215 3.7% 106 0.9% 
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Supplemental Table S3: Adjusted incidence rate ratios for Infection during 2008-15 among all 
patients with diabetes compared to matched controls 
 IRR1 (95%CI) IRR2 (95%CI) IRR3 (95%CI) 
    
Bone & Joint Infections 5.54 (4.89-6.28) 5.19 (4.52-5.96) 4.47 (3.78-5.29) 
(Acute) Cholecystitis 1.63 (1.49-1.78) 1.30 (1.18-1.44) 1.26 (1.12-1.43) 
Endocarditis 1.95 (1.42-2.68) 1.70 (1.18-2.45) 1.53 (0.97-2.43) 
Eye Infection 1.27 (1.23-1.30) 1.21 (1.18-1.25) 1.16 (1.11-1.21) 
Gastro-Intestinal 1.72 (1.65-1.80) 1.58 (1.50-1.66) 1.41 (1.33-1.50) 
Infective Otitis Externa 1.17 (1.12-1.22) 1.03 (0.99-1.08) 0.98 (0.93-1.04) 
LRTI 1.41 (1.38-1.43) 1.24 (1.22-1.26) 1.15 (1.12-1.17) 
Meningitis 1.82 (1.12-2.96) 1.52 (0.88-2.62) 1.88 (0.93-3.80) 
Mycoses - Candidiasis 2.12 (2.05-2.20) 1.81 (1.75-1.89) 1.70 (1.62-1.78) 
Mycoses - Other Fungal 1.26 (1.23-1.30) 1.16 (1.12-1.19) 1.13 (1.09-1.17) 
Pneumonia 1.62 (1.56-1.68) 1.59 (1.53-1.66) 1.48 (1.41-1.55) 
Sepsis 2.34 (2.19-2.50) 2.19 (2.04-2.36) 2.03 (1.86-2.21) 
(Acute) Sinusitis  1.09 (1.05-1.14) 1.02 (0.97-1.07) 0.95 (0.90-1.01) 
Skin - Cellulitis 2.05 (2.00-2.11) 1.51 (1.46-1.56) 1.38 (1.33-1.43) 
Skin - Other 1.75 (1.71-1.79) 1.50 (1.47-1.54) 1.42 (1.38-1.46) 
Surgical Site 1.71 (1.62-1.81) 1.42 (1.33-1.51) 1.24 (1.15-1.33) 
TB 1.68 (1.27-2.23) 2.49 (1.79-3.46) 2.70 (1.80-4.05) 
(Other) URTI 1.27 (1.25-1.30) 1.16 (1.13-1.18) 1.08 (1.06-1.11) 
UTI 1.54 (1.50-1.57) 1.46 (1.42-1.49) 1.37 (1.33-1.42) 
    
Any plus prescription 1.48 (1.46-1.50) 1.31 (1.29-1.32) 1.22 (1.20-1.24) 
Any as hospitalisation1 1.93 (1.88-1.98) 1.74 (1.70-1.79) 1.59 (1.54-1.64) 
Death from infection2 2.00 (1.83-2.20) 2.22 (2.01-2.44) 1.97 (1.76-2.20) 
 
Note: Patients with Type 1 and Type 2 DM have been combined in above table (n=102,493) and compared to 
controls (n=203,518). 
IRR1 – Incidence rate ratios derived from Poisson models conditioned on age, sex and practice   
IRR2 – IRR1 additionally adjusted for BMI, smoking and Index of Multiple Deprivation (IMD) quintile. 
IRR3 – IRR2 additionally adjusted for the following co-morbidities (chronic kidney disease, heart failure, 
hypertension, hypothyroidism, IHD, peripheral vascular disease, stroke & TIA) and whether they had received a 
prescription for a statin or oral steroid in 2007.
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Supplemental Table S4: IRR’s for models excluding controls who become diabetic during the study  
 T2DM (n=96,267) vs. Controls with no 
DM throughout (n=182,161) 
T1DM (n=5,854) vs. Controls with no 
DM throughout (n=11,218) 
 IRR (95%CI) IRR (95%CI) 
Any plus prescription 1.50 (1.48-1.51) 1.71 (1.63-1.79) 
Any as hospitalisation1 1.91 (1.86-1.96) 3.76 (3.31-4.28) 
Death from infection2 1.89 (1.72-2.08) 7.04 (4.10-12.11) 
 
IRR – Incidence rate ratios estimated from conditional Poisson model (age-sex-practice matchsets) 
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Supplemental Table S5: Population attributable risk fractions calculations for selected infection 
groups 
Category Age Group All Ages 
 40-49 50-59 60-69 70-79 80-89 40-89 
       
Total study population1 542,581 432,542 385,903 277,577 182,087 1,820,690 
Prevalence of T2DM2 1.40% 3.86% 6.98% 10.53% 8.89% 5.31% 
Prevalence of T1DM2 0.40% 0.36% 0.29% 0.26% 0.17% 0.32% 
       
Bone & Joint Infections        
- T2DM IRR3 10.34 7.40 4.87 5.20 2.38  
- T2DM PAF4 11.53% 19.80% 21.26% 30.64% 10.92% 19.03%5 
- T1DM IRR3 14.57 39.65 36.77 28.89 5.77  
- T1DM PAF4 5.10% 12.16% 9.40% 6.88% 0.81% 5.82%5 
- Combined PAF6 15.55% 27.82% 27.21% 34.02% 11.56% 22.64%5 
       
Sepsis        
- T2DM IRR3 3.68 3.36 2.45 2.19 1.81  
- T2DM PAF4 3.60% 8.35% 9.22% 11.15% 6.73% 8.14%5 
- T1DM IRR3 9.24 6.06 6.51 5.95 3.45  
- T1DM PAF4 3.16% 1.78% 1.57% 1.29% 0.42% 1.34%5 
- Combined PAF6 6.54% 9.85% 10.52% 12.17% 7.09% 9.29%5 
       
Hospitalisations for Infection        
- T2DM IRR3 3.58 3.02 2.26 1.71 1.42  
- T2DM PAF4 3.48% 7.23% 8.08% 6.99% 3.57% 5.71%5 
- T1DM IRR3 4.61 4.89 3.81 2.99 2.28  
- T1DM PAF4 1.41% 1.37% 0.81% 0.52% 0.22% 0.69%5 
- Combined PAF6 4.79% 8.41% 8.76% 7.45% 3.77% 6.31%5 
       
Death from Infection        
- T2DM IRR3 8.37 5.75 3.68 1.87 1.60  
- T2DM PAF4 9.32% 15.50% 16.20% 8.42% 5.09% 9.75%5 
- T1DM IRR3 15.34 47.11 10.40 9.76 2.90  
- T1DM PAF4 5.37% 14.18% 2.65% 2.28% 0.32% 3.51%5 
- Combined PAF6 13.76% 25.85% 18.07% 10.32% 5.38% 12.44%5 
 
1 - Total number of patients aged 40-89 actively registered on January 1st 2008 from 361 practices in study 
2 - Estimated from total number of patients with DM type (Table 1) divided by total study population in each 
age group 
3 - IRR from conditional Poisson regression stratified by age group (as shown in Figure 2) 
4 - Within each age group, PAF estimated using formula = [Proportion with DM type * (IRR-1)] / [1+ Proportion 
with DM type * (IRR-1)]  
5 - For all-ages PAF, the individual age-group PAF’s are weighted by an estimate of the number of infections in 
the general population in each age-group and summed. Since we do not have access to the records of non-
controls without DM, to estimate the distribution of each infection group by age-group we have had to assume 
that the distribution of infections is equivalent between matched controls and non-controls without DM.   
6 - The PAF estimates for all DM combined were calculated by extending the formula PAF to a scenario where 
the exposure is polytomous. In this case, it is assuming that T1DM and T2DM are non-overlapping exposures 
(see Hanley, J Epidemiol Community Health 2001;55:508–514) 
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Supplemental Table S6: IRR’s for infection during 2008-15 for T1DM vs. T2DM in combined model 
 Type 1 vs Type 2 (n=102,493) 
 IRR1 IRR2 IRR3 
Selected Infections    
- Bone & Joint Infections 2.49 (2.00-3.08) 2.86 (2.31-3.54) 2.54 (2.05-3.14) 
- Pneumonia 1.30 (1.15-1.47) 1.47 (1.30-1.66) 1.40 (1.24-1.58) 
- Sepsis 1.48 (1.23-1.79) 1.72 (1.43-2.08) 1.59 (1.32-1.92) 
Grouped Infections    
- Any plus prescription 0.95 (0.92-0.99) 1.09 (1.05-1.13) 1.06 (1.02-1.10) 
- Any as hospitalisation1 1.30 (1.20-1.40) 1.63 (1.50-1.76) 1.52 (1.40-1.64) 
- Death from infection2 1.93 (1.53-2.44) 2.19 (1.75-2.74) 2.05 (1.64-2.56) 
 
Note: Patients with Type 1 DM (n=5,863) and Type 2 DM (n=96,630) have been directly compared with in 
above table. 
IRR1 – Incidence rate ratios derived from a Poisson model adjusted for age and sex.   
IRR2 – IRR1 additionally adjusted for BMI, smoking and Index of Multiple Deprivation (IMD) quintile. 
IRR3 – IRR2 additionally adjusted for the following co-morbidities (chronic kidney disease, heart failure, 
hypertension, hypothyroidism, IHD, peripheral vascular disease, stroke & TIA) and whether they had received a 
prescription for a statin or oral steroid in 2007. 
 
